Jump to content

Biotie Therapies: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
added page numbers to citation used in infobox
No edit summary
Tags: Mobile edit Mobile web edit Advanced mobile edit
 
(35 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{Short description|Finnish pharmaceutical company}}
{{Infobox company
{{Infobox company
|name = Biotie Therapies Oyj
| name = Biotie Therapies Oyj
|logo = File:Biotie Therapies logo.png
| logo = File:Biotie Therapies logo.png
|type = [[Public company|Publicly traded]]
| type = [[Public company|Public]]
|traded_as = {{OMX|HEX24243|BTH1V}}<br />{{NASDAQ|BITI}}
| traded_as = {{OMX|HEX24243|BTH1V}}<br />{{NASDAQ was|BITI}}
|foundation = 1998
| foundation = {{start date and age|1998}}
|location = [[Turku]], [[Finland]]
| location = [[Turku]], Finland
|key_people = Timo Veromaa <small>([[chief executive officer|CEO]])</small>, Peter Fellner <small>([[Chairman]] of the Board)</small>
| key_people = {{ubl|Markku Jalkanen (founding [[Chief executive officer|CEO]])|Timo Veromaa (CEO)|Peter Fellner ([[chairman]] of the board)}}
|industry = [[Biotechnology]]
| industry = [[Biotechnology]]
|products =
| products =
|revenue = {{gain}} [[Euro|€]] 4.8 million <small>(2012)</small><ref name="fs2012">{{cite web |url=http://hugin.info/132030/R/1683596/551050.pdf |format=PDF |title=Financial statements 2012 |publisher=Biotie Therapies |accessdate=9 March 2013 }}{{Self-published source|date=March 2018}}</ref>{{rp|p. 11}}
| revenue = {{gain}} [[Euro|€]] 4.8 million <small>(2012)</small><ref name="fs2012">{{cite web |url=http://hugin.info/132030/R/1683596/551050.pdf |title=Financial statements 2012 |publisher=Biotie Therapies |access-date=9 March 2013 }}{{Self-published source|date=March 2018}}</ref>{{rp|p. 11}}
|operating_income = {{gain}} (€25.6 million) <small>(2012)</small><ref name="fs2012" />{{rp|p. 11}}
| operating_income = {{gain}} (€25.6 million) <small>(2012)</small><ref name="fs2012" />{{rp|p. 11}}
|num_employees = 38 <small>(end 2012)</small><ref name="fs2012" />{{rp|p. 8}}
| num_employees = 38 <small>(end 2012)</small><ref name="fs2012" />{{rp|p. 8}}
|homepage = [http://www.biotie.com Biotie.com]
| homepage = {{url|http://www.biotie.com}}
|intl = yes
}}
}}


'''Biotie Therapies''' is a [[Finland|Finnish]] [[biotechnology]] and [[pharmaceutics]] company. The company's research and development is focused on drugs for neurodegenerative and psychiatric disorders like [[Parkinson's disease]], [[Alzheimer's disease]] and other [[cognitive disorders]], [[alcohol]] and [[drug dependence]] and [[post traumatic stress disorder]], and [[Inflammation|inflammatory]] and [[fibrosis|fibrotic]] [[liver disease]]. The company's headquarters is in [[Turku]], [[Western Finland]], and it is listed on [[NASDAQ OMX]] Helsinki.
'''Biotie Therapies Oyj''' was a [[Finland|Finnish]] [[biotechnology]] and [[pharmaceutics]] company that was acquired by [[Acorda Therapeutics]] in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like [[Parkinson's disease]], [[Alzheimer's disease]] and other [[cognitive disorders]], [[alcohol (drug)|alcohol]] and [[drug dependence]] and [[post traumatic stress disorder]], and [[Inflammation|inflammatory]] and [[fibrosis|fibrotic]] [[liver disease]]. The company's headquarters is in [[Turku]], [[Western Finland]], and it is listed on [[NASDAQ OMX]] Helsinki.


== Overview ==
== Overview ==
Biotie Therapies was formed in the merger of Biotie Therapies Corp. (incorporated in 1998),<ref>{{cite news
Biotie Therapies was formed in the merger of Biotie Therapies Corp. (incorporated in 1998),<ref>{{cite news
|title=Biotie Therapies on deck for U.S. debut |date=5 June 2015 |work=Seeking Alpha |author=House, Douglas W. |url=http://seekingalpha.com/news/2564956-biotie-therapies-on-deck-for-u-s-debut?ifp=0 }}</ref> Oy Contral Pharma Ltd and Carbion Inc in the year 2002. In 2008, Biotie Therapies acquired the German pharmaceutical discovery and development company elbion GmbH in [[Radebeul]]. In 2010 Biotie Therapies all preclinical assets were transferred into a new company, biocrea GmbH, in which Biotie become a minority shareholder. In 2011, Biotie acquired a pharmaceutical company Synosia.<ref>{{Cite news |url=http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |title=Biotie.com, Investors |date=February 2, 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20110819062317/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |archivedate=2011-08-19 |df= }}</ref>
|title=Biotie Therapies on deck for U.S. debut |date=5 June 2015 |work=Seeking Alpha |author=House, Douglas W. |url=http://seekingalpha.com/news/2564956-biotie-therapies-on-deck-for-u-s-debut?ifp=0 }}</ref> Oy Contral Pharma Ltd and Carbion Inc in the year 2002. In 2008, Biotie Therapies acquired the German pharmaceutical discovery and development company Elbion GmbH in [[Radebeul]]. In 2010 Biotie Therapies all preclinical assets were transferred into a new company, biocrea GmbH, in which Biotie become a minority shareholder. In 2011, Biotie acquired a pharmaceutical company, Synosia.<ref>{{Cite press release |url=http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |title=The acquisition of Synosia Therapeutics Holding AG completed |date=February 2, 2011 |archive-url=https://web.archive.org/web/20110819062317/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1484636&NewsItemYear=2011 |archive-date=August 19, 2011 |url-status=dead|publisher=Biotie Therapies }}{{Self-published source|date=March 2018}}</ref>


The company has partnering agreements with [[Lundbeck|H. Lundbeck A/S]] and [[UCB (company)|UCB]].<ref name="businessweek">[http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?symbol=BTH1V Biotie Therapies Oyj Company Description] Business Week</ref><ref>{{Cite news |url=http://www.biotie.com/en/about_us/collaborations |title=Biotie.com, Collaborations |date=February 14, 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20120427210923/http://www.biotie.com/en/about_us/collaborations |archivedate=2012-04-27 |df= }}</ref>
The company has partnering agreements with [[Lundbeck|H. Lundbeck A/S]] and [[UCB (company)|UCB]].<ref name="businessweek">[https://archive.today/20130118183940/http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?symbol=BTH1V Biotie Therapies Oyj Company Description] Business Week{{Dead link|date=March 2018}}</ref><ref>{{Cite news |url=http://www.biotie.com/en/about_us/collaborations |title=Biotie.com, Collaborations |date=February 14, 2013 |url-status=dead|archive-url=https://web.archive.org/web/20120427210923/http://www.biotie.com/en/about_us/collaborations |archive-date=April 27, 2012 }}{{Self-published source|date=March 2018}}</ref>

In January 2016, Acorda Therapeutics acquired Biotie Therapies for $363 million.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/acorda-acquires-biotie-therapies-for-363m/81252255/|title=Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN|date=19 January 2016 }}</ref>


== Product pipeline ==
== Product pipeline ==
Line 33: Line 35:
! Status
! Status
|-
|-
| Selincro™ ([[nalmefene]])
| Selincro ([[nalmefene]])
| [[alcohol dependence]]
| [[alcohol dependence]]
| [[Lundbeck]]
| [[Lundbeck]]
| EU marketing authorization received <ref name="se280213">{{cite web|url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |title=Biotie: Selincro (nalmefene) receives European marketing authorization |date=28 February 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130603062733/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |archivedate=2013-06-03 |df= }}</ref>
| EU marketing authorization received <ref name="se280213">{{cite press release |url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |title=Biotie: Selincro (nalmefene) receives European marketing authorization |date=28 February 2013 |url-status=dead|archive-url=https://web.archive.org/web/20130603062733/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681977&NewsItemYear=2013 |archive-date=June 3, 2013 |publisher=Biotie Therapies }}{{Self-published source|date=March 2018}}</ref>
|-
|-
| [[Tozadenant]] [[SYN115]]
| Tozadenant SYN115
| [[Parkinson's disease]]
| [[Parkinson's disease]]
| [[UCB (company)|UCB]]
| [[UCB (company)|UCB]]
| [[Phases of clinical research#Phase III|Phase III clinical trials]] to start 2015 <ref name="se270213">{{cite web|url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |title=Stock Exchange Release 27 February 2013 |date=27 February 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130603065527/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |archivedate=2013-06-03 |df= }}</ref>
| [[Phases of clinical research#Phase III|Phase III clinical trials]] to start 2015 <ref name="se270213">{{cite press release |url=http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |title=Stock Exchange Release 27 February 2013 |date=27 February 2013 |url-status=dead|archive-url=https://web.archive.org/web/20130603065527/http://www.biotie.com/en/investors/releases/release?NewsItemID=1681399&NewsItemYear=2013 |archive-date=June 3, 2013 |publisher=Biotie Therapies }}{{Self-published source|date=March 2018}}</ref>
|-
|-
| [[VAP-1]] [[antibody]]
| [[VAP-1]] [[antibody]]
Line 48: Line 50:
| [[Phases of clinical research#Phase I|Phase I clinical trials]] ready, seeking partner
| [[Phases of clinical research#Phase I|Phase I clinical trials]] ready, seeking partner
|-
|-
| [[SYN120]]
| SYN120
| [[AD]], [[cognitive disorder]]s
| [[AD]], [[cognitive disorder]]s
| -
| -
| [[Phases of clinical research#Phase I|Phase I clinical trials]] ready, seeking partner
| [[Phases of clinical research#Phase I|Phase I clinical trials]] ready, seeking partner
|-
|-
| [[Nepicastat]] [[SYN117]]
| [[Nepicastat]] SYN117
| [[PTSD]], [[cocaine dependency]]
| [[PTSD]], cocaine dependency
| [[National Institute on Drug Abuse|NIDA]]
| [[National Institute on Drug Abuse|NIDA]]
| PTSD: [[Phases_of_clinical_research#Phase_IIClinical_trial#Phase II|Phase II clinical trials]], results <ref>[http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1667335&NewsItemYear=2012] Stock Exchange release 27 December 2012</ref> <br />Cocaine dependency: [[Phases of clinical research#Phase II|Phase II clinical trials]], in progress
| PTSD: [[Phases_of_clinical_research#Phase_IIClinical_trial#Phase II|Phase II clinical trials]], results <ref>{{cite press release | url=http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1667335&NewsItemYear=2012 |title=Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder |publisher=Biotie Therapies |date=December 27, 2012 |archive-date=March 4, 2013 |archive-url=https://web.archive.org/web/20130304011035/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1667335&NewsItemYear=2012 }}{{Self-published source|date=March 2018}}</ref> <br />Cocaine dependency: [[Phases of clinical research#Phase II|Phase II clinical trials]], in progress
|-
|-
| [[Ronomilast]]
| Ronomilast
| [[COPD]]
| [[COPD]]
| -
| -
| [[Phases_of_clinical_research#Phase_IClinical_trial#Phase I|Phase I clinical trials]] ready, seeking partner
| [[Phases_of_clinical_research#Phase_IClinical_trial#Phase I|Phase I clinical trials]] ready, seeking partner
|-
|-
| [[Nitisinone]] [[SYN118]]
| [[Nitisinone]] SYN118
| [[Movement disorder]]
| [[Movement disorder]]
| [[UCB (company)|UCB]]
| [[UCB (company)|UCB]]
| [[Phases_of_clinical_research#Phase_IIClinical_trial#Phase II|Phase II clinical trials]], terminated <ref>[https://archive.is/20130407192253/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1565991&NewsItemYear=2011] Stock Exchange release 23 November 2011</ref>
| [[Phases_of_clinical_research#Phase_IIClinical_trial#Phase II|Phase II clinical trials]], terminated <ref>[https://archive.today/20130407192253/http://www.biotie.com/en/investors/stock_exchange_releases/release/?NewsItemID=1565991&NewsItemYear=2011] Stock Exchange release 23 November 2011</ref>
|-
|-
| colspan=5 | <small>''Sources'':<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/development_pipeline |title=Biotie.com, Pipeline |date=February 14, 2013 |deadurl=yes |archiveurl=https://web.archive.org/web/20130215105948/http://www.biotie.com/en/product_and_development/development_pipeline |archivedate=2013-02-15 |df= }}</ref></small>
| colspan=5 | <small>''Sources'':<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/development_pipeline |title=Biotie.com, Pipeline |date=February 14, 2013 |url-status=dead|archive-url=https://web.archive.org/web/20130215105948/http://www.biotie.com/en/product_and_development/development_pipeline |archive-date=2013-02-15 }}</ref></small>
|}
|}


===Selincro™ (nalmefene)===
===Selincro (nalmefene)===


The company's most advanced product, [[Nalmefene]], for the treatment of [[alcoholism]]. Biotie’s partner H. Lundbeck A/S received European marketing authorization from the European Commission on 28 February 2013. Lundbeck expects to launch Selincro in its first markets in middle of 2013.<ref name="se280213" />
The company's most advanced product, [[Nalmefene]], for the treatment of [[alcoholism]]. Biotie's partner H. Lundbeck A/S received European marketing authorization from the European Commission on 28 February 2013. Lundbeck expects to launch Selincro in its first markets in the middle of 2013.<ref name="se280213" />


Studies have shown, that [[nalmefene]] has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five [[unit of alcohol|units of alcohol]]. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time.<ref name="businessweek"/><ref name="nalmefene_phase3">[http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1277334&NewsItemYear=2008 Lundbeck announces start of new phase III clinical trials with nalmefene] {{webarchive |url=https://web.archive.org/web/20081222040053/http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1277334&NewsItemYear=2008 |date=December 22, 2008 }} STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m</ref><ref name="pipeline">[http://www.biotie.com/Webroot/1009506/SubPageWide.aspx?id=1010246 Balanced CNS and inflammation product pipeline] {{webarchive |url=https://web.archive.org/web/20100425231123/http://www.biotie.com/Webroot/1009506/SubPageWide.aspx?id=1010246 |date=April 25, 2010 }} Company website 2008-03-15</ref>
Studies have shown, that [[nalmefene]] has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five [[unit of alcohol|units of alcohol]]. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company, this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time.<ref name="businessweek"/><ref name="nalmefene_phase3">[http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1277334&NewsItemYear=2008 Lundbeck announces start of new phase III clinical trials with nalmefene] {{webarchive |url=https://web.archive.org/web/20081222040053/http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1277334&NewsItemYear=2008 |date=December 22, 2008 }} STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m</ref><ref name="pipeline">[http://www.biotie.com/Webroot/1009506/SubPageWide.aspx?id=1010246 Balanced CNS and inflammation product pipeline] {{webarchive |url=https://web.archive.org/web/20100425231123/http://www.biotie.com/Webroot/1009506/SubPageWide.aspx?id=1010246 |date=April 25, 2010 }} Company website 2008-03-15</ref>


===Tozadenant===
===Tozadenant===


SYN115 also called tozadenant is developed for [[Parkinson's disease]]. The product has a potential to be the first new treatment modality for the disease in more than 20 years. The product is an orally administered, potent and selective inhibitor of the [[adenosine]] 2a receptor. It is being developed for the treatment of [[Parkinson's disease]], but may also have potential for other [[CNS disorders]].<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |title=Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson’s disease |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111228055904/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |archivedate=2011-12-28 |df= }}</ref>
SYN115, also called tozadenant, was developed as a potential treatment for [[Parkinson's disease]] or other [[CNS disorders]].<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |title=Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson's disease |date=March 26, 2012 |url-status=dead|archive-url=https://web.archive.org/web/20111228055904/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn115 |archive-date=2011-12-28 }}</ref> It was an orally administered, potent and [selective [[adenosine A2A receptor antagonist|inhibitor]] of the [[adenosine A2A receptor]].

In January 2016, the company was acquired by [[Acorda Therapeutics]], for {{US$|363 million}}.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/acorda-acquires-biotie-therapies-for-363m/81252255/|title=Acorda Acquires Biotie Therapies for $363 Million|last=Staff|date=January 19, 2016|website=Genetic Engineering & Biotechnology News|publisher=Mary Ann Liebert|location=New Rochelle, New York}}</ref> In November 2017, the company announced discontinuation of the agent following the death of 5 patients enrolled in the tozadenant Phase III trial from [[agranulocytosis]] and associated severe adverse events possibly related to tozadenant.<ref>{{Cite press release|url=http://ir.acorda.com/investors/investor-news/investor-news-details/2017/Acorda-Discontinues-Tozadenant-Development-Program/default.aspx|title=Acorda Discontinues Tozadenant Development Program|website=Investor News|language=en-CA|access-date=2019-09-24|date=November 20, 2017|publisher=Acorda}}{{self-published source|date=September 2019}}</ref><ref>{{Cite web|url=https://www.michaeljfox.org/foundation/news-detail.php?increased-safety-monitoring-in-parkinson-tozadenant-trial|title=Parkinson's Tozadenant Trial Discontinued|last=Dolhun|first=Rachel|date=November 15, 2017|publisher=The Michael J. Fox Foundation for Parkinson's Research|location=New York, New York|access-date=2019-02-14}}</ref>


===VAP-1===
===VAP-1===


[[Vascular Adhesion Protein-1]] (VAP-1) [[monoclonal antibody]] - intended for treatment of [[inflammatory diseases]], is currently in [[Phase I clinical trials]] with [[rheumatoid arthritis]] patients. According to the company, inhibiting VAP-1 reduces [[inflammation]] by regulating the migration of [[leukocyte]]s, or [[white blood cell]]s, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many [[autoimmune disease]]s, such as rheumatoid arthritis, [[ulcerative colitis]], and [[psoriasis]].<ref name="2008Q2">[http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1262893&NewsItemYear=2008 INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - SEPTEMBER 30, 2008]{{dead link|date=November 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>
[[Vascular Adhesion Protein-1]] (VAP-1) [[monoclonal antibody]] - intended for treatment of [[inflammatory diseases]], is currently in [[Phase I clinical trials]] with [[rheumatoid arthritis]] patients. According to the company, inhibiting VAP-1 reduces [[inflammation]] by regulating the migration of [[leukocyte]]s, or [[white blood cell]]s, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many [[autoimmune disease]]s, such as rheumatoid arthritis, [[ulcerative colitis]], and [[psoriasis]].


===Nepicastat===
===Nepicastat===


SYN117 also called nepicastat is a treatment for [[cocaine dependency]] and [[post traumatic stress disorder]] (PTSD). It is orally administered, potent and selective inhibitor of the enzyme dopamine β-hydroxylase (DBH).<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |title=Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD) |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111113105320/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |archivedate=2011-11-13 |df= }}</ref>
SYN117 also called nepicastat is a treatment for cocaine dependency and [[post traumatic stress disorder]] (PTSD). It is orally administered, potent and selective inhibitor of the enzyme dopamine β-hydroxylase (DBH).<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |title=Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD) |date=March 26, 2012 |url-status=dead|archive-url=https://web.archive.org/web/20111113105320/http://www.biotie.com/en/product_and_development/central_nervous_system_disorders/syn117 |archive-date=2011-11-13 }}</ref>


===Ronomilast===
===Ronomilast===


Ronomilast is a PDE4 inhibitor for [[chronic inflammatory disorders]]. It is a small molecule phosphodiesterase-4 inhibitor (PDE4). The product is developed for the treatment of [[chronic obstructive pulmonary disease]] (COPD). Data from pre-clinical and early clinical trials indicates that the product has a good safety profile. Biotie is in the process of planning a Phase 2 trial in COPD patients and also seeking a partner for late-stage development of ronomilast.<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/inflammation/ronomilast |title=Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders |date=March 26, 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20111113101956/http://www.biotie.com/en/product_and_development/inflammation/ronomilast |archivedate=2011-11-13 |df= }}</ref>
Ronomilast is a PDE4 inhibitor for chronic inflammatory disorders. It is a small molecule phosphodiesterase-4 inhibitor (PDE4). The product is developed for the treatment of [[chronic obstructive pulmonary disease]] (COPD). Data from pre-clinical and early clinical trials indicates that the product has a good safety profile. Biotie is in the process of planning a Phase 2 trial in COPD patients and also seeking a partner for late-stage development of ronomilast.<ref>{{Cite news |url=http://www.biotie.com/en/product_and_development/inflammation/ronomilast |title=Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders |date=March 26, 2012 |url-status=dead|archive-url=https://web.archive.org/web/20111113101956/http://www.biotie.com/en/product_and_development/inflammation/ronomilast |archive-date=2011-11-13 }}</ref>


==References==
==References==
Line 99: Line 103:
* [http://www.biotie.fi/?sc_lang=en Company's website]
* [http://www.biotie.fi/?sc_lang=en Company's website]


[[Category:Companies listed on the Helsinki Stock Exchange]]
[[Category:Companies listed on Nasdaq Helsinki]]
[[Category:Pharmaceutical companies of Finland]]
[[Category:Pharmaceutical companies of Finland]]
[[Category:Pharmaceutical companies established in 1998]]
[[Category:Pharmaceutical companies established in 1998]]
[[Category:Companies listed on NASDAQ]]
[[Category:Companies formerly listed on the Nasdaq]]
[[Category:Biotechnology companies of Finland]]
[[Category:Biotechnology companies of Finland]]
[[Category:Parkinson's disease]]
[[Category:Parkinson's disease organizations]]
[[Category:Biotechnology companies established in 1998]]
[[Category:Biotechnology companies established in 1998]]
[[Category:1998 establishments in Finland]]
[[Category:1998 establishments in Finland]]

Latest revision as of 14:06, 8 August 2024

Biotie Therapies Oyj
Company typePublic
Nasdaq Helsinki: BTH1V
Nasdaq: BITI
IndustryBiotechnology
Founded1998; 27 years ago (1998)
HeadquartersTurku, Finland
Key people
  • Markku Jalkanen (founding CEO)
  • Timo Veromaa (CEO)
  • Peter Fellner (chairman of the board)
RevenueIncrease € 4.8 million (2012)[1]: p. 11 
Increase (€25.6 million) (2012)[1]: p. 11 
Number of employees
38 (end 2012)[1]: p. 8 
Websitewww.biotie.com

Biotie Therapies Oyj was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.

Overview

[edit]

Biotie Therapies was formed in the merger of Biotie Therapies Corp. (incorporated in 1998),[2] Oy Contral Pharma Ltd and Carbion Inc in the year 2002. In 2008, Biotie Therapies acquired the German pharmaceutical discovery and development company Elbion GmbH in Radebeul. In 2010 Biotie Therapies all preclinical assets were transferred into a new company, biocrea GmbH, in which Biotie become a minority shareholder. In 2011, Biotie acquired a pharmaceutical company, Synosia.[3]

The company has partnering agreements with H. Lundbeck A/S and UCB.[4][5]

In January 2016, Acorda Therapeutics acquired Biotie Therapies for $363 million.[6]

Product pipeline

[edit]
Name Target indications Partner Status
Selincro (nalmefene) alcohol dependence Lundbeck EU marketing authorization received [7]
Tozadenant SYN115 Parkinson's disease UCB Phase III clinical trials to start 2015 [8]
VAP-1 antibody inflammatory diseases - Phase I clinical trials ready, seeking partner
SYN120 AD, cognitive disorders - Phase I clinical trials ready, seeking partner
Nepicastat SYN117 PTSD, cocaine dependency NIDA PTSD: Phase II clinical trials, results [9]
Cocaine dependency: Phase II clinical trials, in progress
Ronomilast COPD - Phase I clinical trials ready, seeking partner
Nitisinone SYN118 Movement disorder UCB Phase II clinical trials, terminated [10]
Sources:[11]

Selincro (nalmefene)

[edit]

The company's most advanced product, Nalmefene, for the treatment of alcoholism. Biotie's partner H. Lundbeck A/S received European marketing authorization from the European Commission on 28 February 2013. Lundbeck expects to launch Selincro in its first markets in the middle of 2013.[7]

Studies have shown, that nalmefene has the ability to significantly limit both the patient's average alcohol intake and the number of days with an intake above five units of alcohol. The drug works by removing the patient's desire to drink more, thereby controlling and limiting the intake of alcohol. The drug will be used in tablet form, and taken only according to need. According to the company, this is a novel approach for alcohol dependency treatment; existing treatments are aimed at keeping the patient from drinking and the drugs have to be taken continuously over a longer period of time.[4][12][13]

Tozadenant

[edit]

SYN115, also called tozadenant, was developed as a potential treatment for Parkinson's disease or other CNS disorders.[14] It was an orally administered, potent and [selective inhibitor of the adenosine A2A receptor.

In January 2016, the company was acquired by Acorda Therapeutics, for US$363 million.[15] In November 2017, the company announced discontinuation of the agent following the death of 5 patients enrolled in the tozadenant Phase III trial from agranulocytosis and associated severe adverse events possibly related to tozadenant.[16][17]

VAP-1

[edit]

Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody - intended for treatment of inflammatory diseases, is currently in Phase I clinical trials with rheumatoid arthritis patients. According to the company, inhibiting VAP-1 reduces inflammation by regulating the migration of leukocytes, or white blood cells, to inflamed tissues. Pathological accumulation of white blood cells in tissue is a common feature in many autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and psoriasis.

Nepicastat

[edit]

SYN117 also called nepicastat is a treatment for cocaine dependency and post traumatic stress disorder (PTSD). It is orally administered, potent and selective inhibitor of the enzyme dopamine β-hydroxylase (DBH).[18]

Ronomilast

[edit]

Ronomilast is a PDE4 inhibitor for chronic inflammatory disorders. It is a small molecule phosphodiesterase-4 inhibitor (PDE4). The product is developed for the treatment of chronic obstructive pulmonary disease (COPD). Data from pre-clinical and early clinical trials indicates that the product has a good safety profile. Biotie is in the process of planning a Phase 2 trial in COPD patients and also seeking a partner for late-stage development of ronomilast.[19]

References

[edit]
  1. ^ a b c "Financial statements 2012" (PDF). Biotie Therapies. Retrieved 9 March 2013.[self-published source]
  2. ^ House, Douglas W. (5 June 2015). "Biotie Therapies on deck for U.S. debut". Seeking Alpha.
  3. ^ "The acquisition of Synosia Therapeutics Holding AG completed" (Press release). Biotie Therapies. February 2, 2011. Archived from the original on August 19, 2011.[self-published source]
  4. ^ a b Biotie Therapies Oyj Company Description Business Week[dead link‍]
  5. ^ "Biotie.com, Collaborations". February 14, 2013. Archived from the original on April 27, 2012.[self-published source]
  6. ^ "Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN". 19 January 2016.
  7. ^ a b "Biotie: Selincro (nalmefene) receives European marketing authorization" (Press release). Biotie Therapies. 28 February 2013. Archived from the original on June 3, 2013.[self-published source]
  8. ^ "Stock Exchange Release 27 February 2013" (Press release). Biotie Therapies. 27 February 2013. Archived from the original on June 3, 2013.[self-published source]
  9. ^ "Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder" (Press release). Biotie Therapies. December 27, 2012. Archived from the original on March 4, 2013.[self-published source]
  10. ^ [1] Stock Exchange release 23 November 2011
  11. ^ "Biotie.com, Pipeline". February 14, 2013. Archived from the original on 2013-02-15.
  12. ^ Lundbeck announces start of new phase III clinical trials with nalmefene Archived December 22, 2008, at the Wayback Machine STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m
  13. ^ Balanced CNS and inflammation product pipeline Archived April 25, 2010, at the Wayback Machine Company website 2008-03-15
  14. ^ "Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson's disease". March 26, 2012. Archived from the original on 2011-12-28.
  15. ^ Staff (January 19, 2016). "Acorda Acquires Biotie Therapies for $363 Million". Genetic Engineering & Biotechnology News. New Rochelle, New York: Mary Ann Liebert.
  16. ^ "Acorda Discontinues Tozadenant Development Program". Investor News (Press release). Acorda. November 20, 2017. Retrieved 2019-09-24.[self-published source]
  17. ^ Dolhun, Rachel (November 15, 2017). "Parkinson's Tozadenant Trial Discontinued". New York, New York: The Michael J. Fox Foundation for Parkinson's Research. Retrieved 2019-02-14.
  18. ^ "Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD)". March 26, 2012. Archived from the original on 2011-11-13.
  19. ^ "Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders". March 26, 2012. Archived from the original on 2011-11-13.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Biotie_Therapies&oldid=1239298803"